The ability to transfect DNA into cells holds promise to provide for a wide array of uses in both therapeutic and biomedical applications. Recently, researchers at University of Newcastle (Australia) used PLGA (cat# AP041) from PolySciTech Division of Akina, Inc. (www.polyscitech.com) to create nanoparticles which were coated with cationic lipids and PEG-DSPE and utilized these for delivery of DNA. This research holds promise to improve clinical translation of DNA delivery techniques. Santhanes, Diviya, Alex Wilkins, Huiming Zhang, Robert John Aitken, and Mingtao Liang. "Microfluidic formulation of lipid/polymer hybrid nanoparticles for plasmid DNA (pDNA) delivery." International Journal of Pharmaceutics (2022): 122223. https://www.sciencedirect.com/science/article/pii/S0378517322007773
“Abstract: Lipid/polymer hybrid nanoparticles loaded with red fluorescent protein (RFP) encoded plasmid DNA (pDNA) was formulated using poly-lactic-co-glycolic acid (PLGA), cationic lipid DC-cholesterol and surfactant mPEG2000- DSPE. A lipid/ polymer ratio of 1: 10 at 1 mg/ mL surfactant concentration was found to be optimal for producing nanoparticles with diameters of 100- 120 nm that remained stable upon ultracentrifugation. The production of lipid/ polymer hybrid nanoparticles was investigated using microfluidics with a toroidal mixer design. Our results showed that the flow parameters significantly influenced the physicochemical characteristics of nanoparticles and loading of pDNA was only achieved at flow rate ratio (FRR) of 3: 1. The pDNA associated with nanoparticles was demonstrated to be structurally intact using gel electrophoresis, and the encapsulation efficiency (EE) was measured to be ∼65%. The prepared hybrid nanoparticles resulted in 20% of transfection efficacy in human embryonic kidney cells (HEK293T). This study demonstrated the potential of microfluidics in the development of hybrid nanoparticles for pDNA delivery, thus facilitating the clinical translation of DNA therapeutics.”
No comments:
Post a Comment